Heron Therapeutics | HRTX - Current Liabilities


Heron Therapeutics reported $90.52M in Current Liabilities for its fiscal quarter ending in March of 2026.





Current Liabilities Change Date
ALKERMES USD 599.5M 56.06M Mar/2026
Alnylam Pharmaceuticals USD 1.35B 116.87M Mar/2026
Amarin USD 179.64M 14.82M Mar/2026
ANI Pharmaceuticals USD 239.51M 38.6M Mar/2026
Anika Therapeutics USD 20.97M 942K Mar/2026
Arrowhead Research USD 295.22M 52.2M Mar/2026
Eisai JPY 340.25B 47.42B Mar/2026
Emergent BioSolutions USD 651.3M 12.7M Dec/2023
Esperion Therapeutics USD 300.36M 451K Mar/2026
GlaxoSmithKline GBP 22.43B 1.04B Mar/2026
Heron Therapeutics USD 90.52M 5.58M Mar/2026
Insmed USD 361.01M 107.87M Mar/2026
Ligand Pharmaceuticals USD 40.67M 3.22M Mar/2026
Merck USD 26.94B 1.38B Mar/2026
Nektar Therapeutics USD 53.54M 12.8M Dec/2025
Neurocrine Biosciences USD 831.7M 88.3M Mar/2026
Omeros USD 85.5M 2.28M Jun/2025
Pacira USD 108.79M 11.8M Mar/2026
Regeneron Pharmaceuticals USD 5.11B 739.3M Mar/2026
Roche Holding CHF 28B 421M Dec/2025
Sangamo BioSciences USD 47.66M 1.9M Jun/2025
Ultragenyx Pharmaceutical USD 325M 59M Mar/2026
Veracyte USD 56.11M 3.82M Mar/2026
Vertex Pharmaceuticals USD 3.88B 19.4M Mar/2026